LAS VEGAS, Sept. 30, 2013 /CNW/ - Vansen Pharma Inc. [OTCBB: VNSN] is pleased to announce that effective today the company's common shares will begin trading under its new ticker symbol, "VNSN".
The Financial Industry Regulatory Authority (FINRA) previously approved the company's request to change its name from Okana Ventures Inc. (OTCBB: OKNVD) to Vansen Pharma Inc., better reflecting the nature of its core business operations.
About Vansen Pharma Inc.
Vansen Pharma Inc. is a specialty pharmaceutical company focused on broad therapeutic areas that are anticipated to grow and present an opportunity for major expansion. Vansen will expand its commercial presence by adding complimentary products through in-licensing, co-promotion and acquisitions, resulting in a comprehensive product portfolio. With its US based sales force, Vansen can better serve the increasing healthcare needs of patients and enhance growth.
Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Vansen's actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Vansen's products, changes in competition, the ability of Vansen to integrate acquisitions or complete future acquisitions, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Vansen that Vansen's plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.
SOURCE: Vansen Pharma Inc.
For further information:
Vansen Pharma Inc.
President and CEO